Citi initiated coverage of Henry Schein (HSIC) with a Buy rating and $100 price target The firm launched the animal health and dental sectors with a “cautiously optimistic” view. Citi favors the animal health group, saying the the “humanization” pet trend is real and should drive more spending. The firm’s top pick is Zoetis. It sees the weak macro backdrop pressuring the dental sector. Citi expects a trade-down to lower cost implants and orthodontics. Citi’s top dental pick is Henry Schein.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HSIC:
- Henry Schein price target lowered to $90 from $100 at Evercore ISI
- Henry Schein to reduce size of board of directors following annual meeting
- Henry Schein price target raised to $97 from $79 at Barrington
- Henry Schein price target raised to $104 from $100 at Baird
- Henry Schein price target raised to $87 from $79 at UBS
